| HOME >> BIOLOGY >> TECHNOLOGY |
Similar to last year, Chinese growth companies continue to have a high regard for growth prospects across the Asia Pacific region. 71% of the surveyed companies have an optimistic view of development in the region. These CEOs also believe the Asia Pacific region presents the most attractive market growth opportunities. Additionally, 77% of CEOs said they pay much more attention to the regional market, which is attracting enterprises seeking advanced development opportunities.
Talking about future, 94% of CEOs remain confident that the region will continue to experience a high growth rate over the next 12 months. 46% of CEOs do not believe the world economic depression has affected their business. They are actively adopting corresponding measures, such as attracting talent from developed markets and seeking acquisition opportunities in the developed markets.
About the Deloitte Technology Fast 50
The Deloitte Technology Fast 50 program started in 1995 in San Jose. This program quickly expanded to numerous cities and countries. In 2005, Deloitte China launched the "Deloitte Technology Fast 50 China" program. Participants in the Deloitte Technology Fast 50 China program will automatically qualify for participation in the Deloitte Technology Fast 500 Asia Pacific 2008 program, which annually recognises the 500 fastest growing technology companies in Asia Pacific.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's
commercialized vaccines include Healive(R) (hepatitis A), Bilive(R)
(combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1).
Sinovac is currently dev
'/>"/>
| SOURCE Sinovac Biotech Ltd. Copyright©2008 PR Newswire. All rights reserved |